Cipla Limited has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) on 10th April 2023 to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from 1st January 2026.

The agreement is subject to satisfaction of certain conditions precedent. During the interim period, the company would continue to market and distribute Galvus branded products.

Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category. Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore (IQVIA MAT February 2023).

This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category.